Zhengyuan Wang

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

2021 | Lékařská fakulta v Hradci Králové

Publikace